## Topo II Alpha Recombinant Monoclonal Antibody [BLR358N]



Rabbit Recombinant Monoclonal

Purified RefSeq ID NP\_001058.2

Catalog No. A700-358-T Uniprot ID P11388

Lot No. 1 GenelD 7153

**APPLICATIONS** WB, IHC, ICC

SPECIES REACTIVITY Human, Mouse

AMOUNT 10 µl (5+ tests)

CONCENTRATION 500 μg/ml

**STORAGE/SHELF LIFE** 2 – 8°C / 1 year from date of receipt

PHYSICAL STATE Liquid

**BUFFER** Phosphate Buffered Saline (PBS) with 0.1% BSA and 0.09% Sodium Azide

**ISOTYPE** IgG

CLONE # BLR358N

ORIGIN USA

**PRODUCTION** 

Recombinant antibody was purified from cell culture supernatant.

PROCEDURES

Immunogen was a pentide representing a region between residue 650 and

Immunogen was a peptide representing a region between residue 650 and 700 of human DNA topoisomerase 2-alpha using the numbering given in entry NP\_001058.2 (Gene ID

7153).

**APPLICATIONS** Centrifuge tube to remove product from lid. Optimal working dilutions should be determined

experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot 1:1,000

Immunohistochemistry 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is

recommended for FFPE tissue sections.

Immunocytochemistry 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is

recommended for FFPE cell sections.

**APPLICATION NOTES** All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent.

Primary antibody is incubated overnight.

Western blots of cell lysates are performed using Goat anti-Rabbit IgG Heavy and Light Chain

Antibody (A120-101P).

IHC HUMAN CONTROLS Breast Carcinoma, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinoma, GaMG Cells, K-

562 Cells

IHC MOUSE CONTROLS Spleen, Testis, Thymus, CH27 Cells, CTLL-2 Cells

ADDITIONAL INFO https://www.fortislife.com/p/A700-358-T

Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Michael Spencer, PhD

Date: March 28, 2025